We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) recently announced the launch of Gibco CTS Detachable Dynabeads (“CTS Detachable Dynabeads”). The next-generation platform of Dynabeads comes with the first-of-its-kind active release mechanism for clinical trials and commercial manufacturing use.
The CTS Detachable Dynabeads platform works within TMO’s modular, closed and automated cell therapy manufacturing workflow. The latest development represents a new generation of cell therapy isolation and activation products that prioritize patient quality and safety while simultaneously creating greater workflow control for Thermo Fisher’s customers.
News in Detail
The active release mechanism of CTS Detachable Dynabeads utilizes a release buffer that enables users to actively detach Dynabeads from a target cell at any point during their manufacturing process. This helps save manufacturing costs while delivering high cell purity, yield and viability. These manufacturing benefits can help cell therapy developers get more life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancer.
Image Source: Zacks Investment Research
CTS Detachable Dynabeads offer process flexibility, compatibility with automation and scalability through its differentiating active release mechanism. This functionality for cGMP and clinical use helps empower users to achieve greater control of their processes, with the ability to consistently deliver target cells with the desired characteristics for their therapy.
Cell recovery, phenotype and viability for downstream steps within the workflow are also optimized through this platform. These advantages are critical for scaling cell therapy manufacturing while maintaining a consistent performance in the transition from process development to clinical trials and commercial manufacturing.
The first offering within this platform is the CTS Detachable Dynabeads CD3/CD28 Kit, which is specifically designed to help manufacturers isolate and actively target T cells in a one-step mechanism. The CTS Detachable Dynabeads CD3/CD28 Kit of isolation and activation reagents will serve both autologous and allogeneic manufacturing processes across multiple cell modalities.
Industry Prospects
Per a Research report, the global cell and gene therapy market was valued at $7.28 billion in 2022 and is expected to witness a CAGR of 26.6% in the 2023-2030 period.
Strategic Boosts for Cell Therapy Developments
Thermo Fisher’s Gibco Cell Culture for Bioprocessing, Chromatography and Protein Purification is already in high demand. As a key pillar of the growth strategy, Thermo Fisher is leveraging its scale and high growth in emerging markets to create a differentiated experience for its customers.
The company is strengthening its capabilities serving emerging markets by opening a new Gibco cell culture rapid prototyping facility at its existing site in Suzhou, China. This facility will help regional customers accelerate the transition of their cell culture media production to current good manufacturing practices.
The new cell therapy cGMP Manufacturing and Collaboration Center, built in collaboration with the University of California, San Francisco, offers solutions for cell therapy development — from discovery to clinical research through commercial manufacturing. Thermo Fisher sees immense potential in partnerships like this to transform clinical care.
Price Performance
In the past six months, TMO shares have decreased 3.9% against the industry’s rise of 5.2%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Haemonetics stock has risen 14.4% in the past year. Earnings estimates for Haemonetics have increased from $3.58 to $3.82 in 2023 and $3.98 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have soared 149.6% in the past year against the industry’s decline of 5.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.33 to $1.25 per share in the past 30 days. Shares of the company have rallied 21.9% in the past year compared with the industry’s rise of 3.3%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
Thermo Fisher Scientific (TMO - Free Report) recently announced the launch of Gibco CTS Detachable Dynabeads (“CTS Detachable Dynabeads”). The next-generation platform of Dynabeads comes with the first-of-its-kind active release mechanism for clinical trials and commercial manufacturing use.
The CTS Detachable Dynabeads platform works within TMO’s modular, closed and automated cell therapy manufacturing workflow. The latest development represents a new generation of cell therapy isolation and activation products that prioritize patient quality and safety while simultaneously creating greater workflow control for Thermo Fisher’s customers.
News in Detail
The active release mechanism of CTS Detachable Dynabeads utilizes a release buffer that enables users to actively detach Dynabeads from a target cell at any point during their manufacturing process. This helps save manufacturing costs while delivering high cell purity, yield and viability. These manufacturing benefits can help cell therapy developers get more life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancer.
Image Source: Zacks Investment Research
CTS Detachable Dynabeads offer process flexibility, compatibility with automation and scalability through its differentiating active release mechanism. This functionality for cGMP and clinical use helps empower users to achieve greater control of their processes, with the ability to consistently deliver target cells with the desired characteristics for their therapy.
Cell recovery, phenotype and viability for downstream steps within the workflow are also optimized through this platform. These advantages are critical for scaling cell therapy manufacturing while maintaining a consistent performance in the transition from process development to clinical trials and commercial manufacturing.
The first offering within this platform is the CTS Detachable Dynabeads CD3/CD28 Kit, which is specifically designed to help manufacturers isolate and actively target T cells in a one-step mechanism. The CTS Detachable Dynabeads CD3/CD28 Kit of isolation and activation reagents will serve both autologous and allogeneic manufacturing processes across multiple cell modalities.
Industry Prospects
Per a Research report, the global cell and gene therapy market was valued at $7.28 billion in 2022 and is expected to witness a CAGR of 26.6% in the 2023-2030 period.
Strategic Boosts for Cell Therapy Developments
Thermo Fisher’s Gibco Cell Culture for Bioprocessing, Chromatography and Protein Purification is already in high demand. As a key pillar of the growth strategy, Thermo Fisher is leveraging its scale and high growth in emerging markets to create a differentiated experience for its customers.
The company is strengthening its capabilities serving emerging markets by opening a new Gibco cell culture rapid prototyping facility at its existing site in Suzhou, China. This facility will help regional customers accelerate the transition of their cell culture media production to current good manufacturing practices.
The new cell therapy cGMP Manufacturing and Collaboration Center, built in collaboration with the University of California, San Francisco, offers solutions for cell therapy development — from discovery to clinical research through commercial manufacturing. Thermo Fisher sees immense potential in partnerships like this to transform clinical care.
Price Performance
In the past six months, TMO shares have decreased 3.9% against the industry’s rise of 5.2%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) . Each of these companies presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics stock has risen 14.4% in the past year. Earnings estimates for Haemonetics have increased from $3.58 to $3.82 in 2023 and $3.98 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have soared 149.6% in the past year against the industry’s decline of 5.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.33 to $1.25 per share in the past 30 days. Shares of the company have rallied 21.9% in the past year compared with the industry’s rise of 3.3%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.